TSE:VMD

10.45
0.29 (2.85%) 1d
0

Related posts

Top 4 Canadian Healthcare Stocks Catapult by the Worldwide Aging Demographic
Investor Insights

This summary was created by AI, based on 3 opinions in the last 12 months.

Viemed Healthcare (VMD-T) has shown positive momentum and growth, with recent earnings beating estimates and strong fundamentals. The company has seen revenue and earnings growth, with a positive cash flow and no debt. Despite a recent earnings miss, the overall results are considered decent, although the stock is highly volatile. The business continues to grow and trade at a reasonable PE, indicating a fundamentally sound business.

Consensus
Positive
Valuation
Fair Value
Similar
Amphastar Pharmaceuticals, AMPH
HOLD
Viemed Healthcare
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

Momentum has been improving recently and VMD is up 10% year-to-date. Recent earnings were positive with the stock beating EPS and revenue estimates and continuing to grow positively. The stock continues to look good fundamentally with positive, growing free cash flows and a net cah balance. Its valuation at 25x forward earnings is also not bad given the strong earnings and revenue growth expected over the next few years. We think it is be worth holding as it is a fundamentally sound business in our opinion. 
Unlock Premium - Try 5i Free 

0
HOLD
Viemed Healthcare
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

EPS of $0.04 missed estimates of $0.07 and revenues of $50.6M beat estimates of $49.9M. Revenues grew by 28% year-over-year, and its Adjusted EBITDA grew by 21%. It has no debt and management expects to generate revenues of $53.8M to $54.8M for Q2 2024. It was cash flow negative for the quarter, but its margins are good and it has a strong balance sheet. For a company growing fast with good profit margins, it is only trading at 20X forward earnings, but it is highly volatile and a small name. We consider the results overall decent, but investors are likely not pleased with its earnings miss.
Unlock Premium - Try 5i Free

0
PAST TOP PICK
Viemed Healthcare
(A Top Pick Jun 01/22, Up 51%)

Their numbers continues to soar, but shares fell last year over concerns that the hit diet drugs will impact them. But business continues to bs strong as they grow revenues and earnings. Trades at a reasonable PE.

0
premium

It's a Monthly Gems opinion which is available only for Premium members

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK
Viemed Healthcare

When markets hit 52-week highs and signs point to frothiness, where do you put your money? The safe route is a savings account paying 5%. The riskier one, but could pay you more later, lies in unloved sectors. Healthcare is one. As a ventilator company, Viemed thrived during the pandemic, which explains its 174% rise in the last five years. This year has been a different story as VMD jumped to $16.25 last April, but has sunk to $11.50. (These are its TSX prices. This Louisiana-based company trades on the NYSE as well.)

0
PAST TOP PICK
Viemed Healthcare

(A Top Pick Jun 01/22, Up 73%)

Excellent performance in stock reflective of demand for healthcare tech.
Continues to hold.
Happy with results.

0
BUY
Viemed Healthcare
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research.

VMD EPS of 4c beat estimates of 3.5c; Revenue of $39.6M beat estimates of $38.5M. EBITDA of $8.3M beat estimates by 3%. Sales rose 23%; EPS though was flat year over year. EBITDA rose 15%. 2Q  Guidance was maintained and another acquisition was announced. Cash rose to $23.5M (no debt). We would consider it a good quarter. 
Unlock Premium - Try 5i Free

0
BUY
Viemed Healthcare
Their ventilator business has grown in recent years tough they struggled to access Covid patients in hospitals. They had great revenues in their last quarter. They're expanding operations as they enter new markets. EBITDA was lower than expected, so shares pulled back. They trade at half the PE of their peers. The CEO is one of the biggest shareholders. (Analysts’ price target is $15.86)
0
TOP PICK
Viemed Healthcare
In-home, non-invasive respiratory devices. Grows organically and by acquisition. Earnings beat for second consecutive quarter. Awesome management. Growing phenomenally, projected 25% topline growth over next year. Profitable, big cash balance, buying back stock. Discount to peers. NASDAQ listing should generate interest. (Analysts’ price target is $15.01)
0
PAST TOP PICK
Viemed Healthcare
(A Top Pick Apr 27/20, Up 16%) Covid has indirectly increased their business. Growing organically and via acquisitions. Reasonable multiple. Either multiple expansion or a takeover target.
0
BUY
Viemed Healthcare
There is a lot of growth in this name. They had a bit of a windfall selling equipment during COVID. There is a lot of positive news coming out about their in-home care. There are a lot of positive drivers in this business.
0
TOP PICK
Viemed Healthcare
Enjoys strong tailwinds from aging demographics though Covid made it difficult to access older patients. They continue to be acquisitive. Good valuation. They release earnings shortly and this could move the stock higher. He recently bought this. (Analysts’ price target is $16.02)
0
DON'T BUY
Viemed Healthcare

He didn't like it for a while, but now more than before. The telehealth space is getting crowded and they've had issues with CMS code. It's a good American company, though doesn't receive much attention here. VMS is merely okay. He prefers other names like Knight Therapeutics. It's a decent, second-tier company.

0
HOLD
Viemed Healthcare
He got stopped out of it a while ago. VMD relies on Medicare for a lot of revenues. Clients use sleep-aid systems that are put through Medicare. This revenue stream is coming up for review by Medicare , so this is a risk. Otherwise, VMD checks a lot of boxes. Hold.
0
BUY
Viemed Healthcare
They provide home equipment and therapy to deal with sleep apnea and other respiratory issues. Earnings are expected to grow 75%. 2021 ROE 37% as earnings rocket up, expected to jump 85% in 2020 and 16% in 2021. PE is 18x 2020, and 22x in 2021. Positive free cash flow which should double. It could join a U.S. index which will boost the stock. $15.25 price target or 9% upside.
0
TOP PICK
Viemed Healthcare
They provide non-invasive ventilators. Medicare is no longer going through a competitive bidding process. (Analysts’ price target is $13.07)
0
Showing 1 to 15 of 26 entries

Viemed Healthcare(VMD-T) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 3

Stockchase rating for Viemed Healthcare is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Viemed Healthcare(VMD-T) Frequently Asked Questions

What is Viemed Healthcare stock symbol?

Viemed Healthcare is a Canadian stock, trading under the symbol VMD-T on the Toronto Stock Exchange (VMD-CT). It is usually referred to as TSX:VMD or VMD-T

Is Viemed Healthcare a buy or a sell?

In the last year, 3 stock analysts published opinions about VMD-T. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Viemed Healthcare.

Is Viemed Healthcare a good investment or a top pick?

Viemed Healthcare was recommended as a Top Pick by on . Read the latest stock experts ratings for Viemed Healthcare.

Why is Viemed Healthcare stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Viemed Healthcare worth watching?

3 stock analysts on Stockchase covered Viemed Healthcare In the last year. It is a trending stock that is worth watching.

What is Viemed Healthcare stock price?

On 2023-12-21, Viemed Healthcare (VMD-T) stock closed at a price of $10.45.